Korea’s Celltrion is continuing to think bigger than biosmilars, this time securing the option to use TriOar’s antibody ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional ...

“Under Belgian rules, you can't really do that because it takes a 75% vote,” Gosebruch explained. “Gilead owns 25% and ...

As the biopharma world predominantly zeroes in on late-stage assets, Eli Lilly is prioritizing early science with the opening ...

Cytokinetics may be counting down the days until the FDA decides whether to approve its cardiovascular drug aficamten. | ...

JSR Life Sciences is parting ways with its CRO business Crown Bioscience, selling the unit to a Chinese clinical lab service ...

Medtronic posted a slate of strong quarterly financial results this morning, with its cardiovascular device portfolio pushing ...

GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

The investment bank Jefferies had been running its healthcare conference in London for 14 years as a reasonably intimate ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...